Nifedipine XL BID
ApprovedSmall molecule
Nifedipine XL BID is one of 20 small molecule programs targeting Hypertension. It is currently in Approved.
1
Indications
1
Total Trials
1
Active Trials
19
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
566 competitors in Hypertension
#DrugCompanyPhaseTrials
1Nifedipine XL BID
NNebraska Methodist Health System
Approved
Zebeta
TevaPreclinical
Aceon
Institut de Recherches Internationales ServierPreclinical
Winrevair
Merck & Co.Preclinical
Deltavit
HHyundai Pharmaceutical Co., LTD.
Preclinical
Ultiva
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Avastin
BBio-Thera Solutions
Preclinical
Vivarin
HHikma Pharmaceuticals LLC
Preclinical
Inderal
Mylan Pharmaceuticals IncPreclinical
Salbutamol
GSKPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Nifedipine XL BID. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- NNebraska Methodist Health System